Pharmalytics Group specializes in strategy and advanced analytics for pharmaceutical market access. The company provides services in health technology assessment, evidence synthesis, real-world evidence generation, and decision analytics.

Pharmalytics Group

Ken Mulvany

Ivan Griffin

Brent Gutekunst

Michael Brennan

BenevolentAI S.A.

GSK plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, HIV, immuno-inflammation, oncology, anti-viral, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterial, and dermatology. It also provides consumer healthcare products in wellness, oral health, nutrition, and skin health categories. The company offers its consumer healthcare products in the form of nasal sprays, tablets, syrups, lozenges, gum and trans-dermal patches, caplets, infant syrup drops, liquid filled suspension, wipes, gels, effervescents, toothpastes, toothbrushes, mouthwashes, denture adhesives and cleansers, topical creams and non-medicated patches, lip balm, gummies, and soft chews. It has collaboration agreements with 23andMe; Lyell Immunopharma, Inc.; Novartis; Sanofi SA; Surface Oncology; Progentec Diagnostics, Inc.; Alector, Inc.; and CureVac AG., as well as strategic partnership with IDEAYA Biosciences, Inc. and Vir Biotechnology, Inc. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.

John Smith

Nicholas Babaian

GSK plc

Metis Consulting Services is a boutique international consultancy focused on providing strategic solutions and GxP services for the biotech and pharmaceutical industries. The company specializes in services including AI for Life Sciences, Clinical Data Management, and Regulatory Strategy Advising.

Metric
Company Name	Pharmalytics Group	BenevolentAI S.A.	GSK plc	Metis Consulting Services
Symbol		BAI	GSK
MSH ID	COM:PHARMALYTICSGROUP	COM:BENEVOLENT	COM:GSK	COM:METISCONSULTINGSERVICES
Market	PRIVATE	STOCKS	STOCKS	PRIVATE
Sector	Commercial & Professional Services		Healthcare	Commercial & Professional Services
Industry	Healthcare & Health Services		Drug Manufacturers - General	Biotechnology and Pharmaceuticals
Country	US		GB	US
Stage
Employee Count			70.21K
Website	pharmalyticsgroup.com		gsk.com	metisconsultingservices.com
LinkedIn
Founders

Metric
Market Cap		786.32M
Enterprise Value
Monthly Web Traffic	12.91K	1.33M
Web Traffic Growth	0.76	0.02
Valuation
Raised Capital

Metric
Revenue	9.34M	38.64B
Revenue (LTM)
Revenue (NTM)
Gross Profit	9.34M	27.08B
EBITDA	-89.02M	11.83B
Operating Income	-98.85M	8.91B
Net Income	-80.68M	6.28B
EPS		1.55
Diluted EPS		1.53
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	1	0.73
Operating Profit Margin	-10.58	0.26
EBITDA Margin	-9.53	0.31
Net Profit Margin	-8.64	0.16
Return on Equity	-0.51	0.39
Return on Assets	-0.51	0.08
Return on Capital Employed	-0.79	0.20

PHAR

COM:PHARMALYTICSGROUP

Pharmalytics Group

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	-0.43	11.10
P/B Ratio	0.46	5.13
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	12.42	2.37
EV Multiple	-0.82	5.83

Metric
Days Sales Outstanding
Days Payables Outstanding		678.29
Days Inventory Outstanding		247.86
Operating Cycle		338.14
Cash Conversion Cycle		-264.26
Asset Turnover	0.06	0.54

Metric
Operating Cash Flow	-72.79M	8.09B
Free Cash Flow	-74.20M	5.10B
Cash Flow to Debt	-10.46	0.42
Operating Cash Flow/Sales	-7.28	0.24
Free Cash Flow Yield	-1.03	0.05

Metric
Cash & Equivalents	46.48M	3.74B
Accounts Receivable		-826.97M
Inventory		7.01B
Goodwill	29.92M	8.68B
Debt to Capitalization	0.05	0.56
Debt to Assets	0.04	0.34
Current Ratio	5.93	0.95
Quick Ratio	3.65	0.60

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	3.20
R&D to Revenue	6.16	0.20
SG&A to Revenue	3.03	0.31